The U.S. Securities and Exchange Commission (SEC) has issued a final judgment against stock salesman Carl Smith for his role in Nanobeak Biotech Inc..Misrepresentation made to investors when raising funds。

The decision was handed down by the U.S. District Court for the Southern District of New York in early January.。

According to a complaint filed by the SEC on December 9, 2020, between at least December 2015 and December 2019, Nanobeak Biotech and its former CEO Jeremy Barbera used false and misleading statements to solicit and sell Nanobeak Securities.。During that time, Nanobeak and Barbera, with the help of Smith, sold securities to at least 37 investors, raising a total of about $3.6 million.。

Smith agreed to make a final judgment permanently prohibiting him from violating Section 17 (a) of the Securities Act of 1933 and Section 10 (b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.。The final judgment also ordered Smith to pay a $100,000 civil fine and ordered him to surrender $173,875, plus 23,470..Pre-trial interest of $59。